Companies secure £382 million in financing, up 29 per cent from previous quarter
UK biotech investment increased by almost 30 per cent in the second quarter of 2023 despite the global market downturn, according to new data.
UK-headquartered life science and biotech companies secured a total of £382 million in venture and public financing, up 29 per cent from the previous quarter’s £295m, a report from the global analytics firm Clarivate* and the Bioindustry Association trade body has revealed.
This article is only available to Research Professional News subscribers or Pivot-RP users.
If you are a Research Professional News subscriber you can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.